Labcorp Q2 revenue up 5.8% to $3.73B, adjusted EPS $4.99 beats; raises FY guidance

LABCORP HOLDINGS INC.

Q2 diluted EPS $3.64 vs $2.84 (+28.5%); adjusted EPS $4.99 vs $4.35 (+14.9%), beating prior guidance.
Revenue $3.73B, up 5.8% YoY; Diagnostics Labs +5.5%, Biopharma +6.5%.
Raised FY 2026 adjusted EPS guidance to $18.10-$18.55 (up $0.30 at midpoint); revenue growth 5.4%-6.3%.
Board approved $1.0B increase in share repurchase authorization, total remaining $1.4B.
Completed acquisitions of Parkview Health outreach services and Tribal Diagnostics; quarterly dividend $0.72.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.